预约演示
更新于：2026-09-01
Zenagamtide
泽那加肽
更新于：2026-09-01
概要
基本信息
药物类型 多肽激素 |
别名 Amycretin、NN-9487、NN9487 + [2] |
作用方式 激动剂 |
作用机制 AMYR 激动剂(胰淀素受体 激动剂)、GLP-1R激动剂(胰高血糖素样肽-1激动剂) |
在研适应症 |
非在研适应症- |
原研机构 |
非在研机构- |
权益机构- |
最高研发阶段临床3期 |
首次获批日期- |
最高研发阶段(中国)临床3期 |
特殊审评- |
登录后查看时间轴
结构/序列
Sequence Code 1098281922
来源: *****
关联
27
项与 泽那加肽 相关的临床试验NCT07668401
Efficacy and Safety of Zenagamtide s.c. Once-weekly in Asian Participants With Overweight or Obesity (AMAZE 13)
NCT07668414
Efficacy and Safety of Zenagamtide s.c. Once-weekly Compared to Semaglutide s.c. Once-weekly in Participants With Obesity (AMAZE 7)
CTIS2025-521383-35-00
A research study looking at the effect of timing of meal after dosing and water volume at dosing on how the medicine zenagamtide is taken up by the body of participants with overweight or obesity
100 项与 泽那加肽 相关的临床结果
登录后查看更多信息
100 项与 泽那加肽 相关的转化医学
登录后查看更多信息
100 项与 泽那加肽 相关的专利（医药）
登录后查看更多信息
16
项与 泽那加肽 相关的文献（医药）2026-06-01METABOLISM-CLINICAL AND EXPERIMENTAL
Amycretin in obesity: Mechanisms, clinical efficacy, and future perspectives
Review
作者: Yang, Pingping ; Hu, Jinzhu ; Fu, Linghua ; Xu, Gaosi ; Ding, Rui
The global escalation of obesity necessitates therapeutic interventions that transcend the efficacy ceilings of current mono-target pharmacotherapies. Amycretin, a novel unimolecular co-agonist targeting glucagon-like peptide-1 (GLP-1) and amylin receptors, has emerged as a promising candidate for weight management. In this review, we examine the developmental rationale of amycretin, elucidating how its dual-agonist mechanism synergistically engages hindbrain-mediated satiety pathways and delays gastric emptying to overcome metabolic plateaus. We summarize pivotal findings from recent clinical trials, highlighting that amycretin elicits profound weight reduction-demonstrating up to 13.1% loss with oral administration (12 weeks) and 24.3% with subcutaneous delivery (36 weeks)-with a safety profile consistent with incretin-based classes. Furthermore, we explore the strategic potential of combining amycretin with insulin-independent agents, such as SGLT2 inhibitors, to optimize cardio-renal outcomes. These insights provide a theoretical framework for positioning amycretin in the future management of adiposity-based chronic diseases.
2026-05-01Lancet Diabetes & Endocrinology
Beyond weight loss: multisystem benefits of obesity medications
Review
作者: van Rossum, Elisabeth F C ; Savas, Mesut ; Kuckuck, Susanne ; Boon, Mariëtte R
Obesity is increasingly managed with medications as disease-modifying therapies, reflecting its role as a gateway disease driving metabolic, cardiovascular, reproductive, neuropsychiatric, and mechanical conditions. This Review synthesises evidence from randomised controlled trials and high-quality meta-analyses on approved and late-stage investigational obesity medications, including phentermine-topiramate, naltrexone-bupropion, glucagon-like peptide-1 (GLP-1) receptor agonists (eg, liraglutide, semaglutide, subcutaneously and orally), and newer GLP-1 receptor agonist-based agents (eg, tirzepatide, survodutide, mazdutide, retatrutide, cagrilintide-semaglutide, and amycretin). We evaluated the effects of obesity medications across major obesity-related conditions, including type 2 diabetes, metabolic dysfunction-associated steatotic liver disease, chronic kidney disease, heart failure, cardiovascular disease, obstructive sleep apnoea syndrome, polycystic ovary syndrome (recently named polyendocrine metabolic ovarian syndrome), osteoarthritis, muscle mass, depression, quality of life, and food cravings, along with binge-eating disorders, substance use disorders, and neurodegenerative diseases. Overall, GLP-1-based and multiagonist therapies show beneficial effects across these comorbid conditions. While many benefits of obesity medications are mediated by weight loss, accumulating evidence indicates important weight loss-independent effects, particularly with GLP-1 receptor agonist-based therapies. A broader understanding of these pleiotropic effects is essential to inform personalised obesity management and optimise long-term clinical outcomes.
2026-05-01Endocrinology, diabetes & metabolism
Novel Amylin‐Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A Network Meta‐Analysis
Review
作者: Khalil, Ibrahim ; Kamrul‐Hasan, A. B. M. ; Dutta, Deep ; Mahajan, Kunal ; Pappachan, Joseph M. ; Banerjee, Mainak
ABSTRACT:
Background:
Long‐acting amylin‐based therapies (ABTs) are emerging anti‐obesity agents; we sought to compare their effects on weight and anthropometric outcomes in adults with overweight/obesity without diabetes, evaluate gastrointestinal (GI) safety, and rank agents and doses within a network meta‐analysis (NMA) framework.
Methods:
We conducted a frequentist random‐effects NMA of randomized controlled trials comparing novel ABTs with placebo or active comparators in R. Primary outcome was the percent change in body weight from baseline. Secondary outcomes included absolute weight changes, anthropometric measures, and overall and specific GI adverse events (AEs). Treatments (including dose strata) were compared with placebo within a single network and ranked using P scores.
Results:
Six trials (
N
= 4642; 12–68 weeks) were included. Compared with placebo, high dose (HiD) subcutaneous amycretin produced the largest reduction in percent body weight (mean difference −23.95%; P score 1.00), followed by HiD eloralintide (−18.01%; P score 0.89) and HiD CagriSema (−17.18%; P score 0.85), all exceeding semaglutide 2.4 mg (−11.45%) and liraglutide 3.0 mg (−6.4%). Almost similar patterns were observed for absolute weight, body mass index, waist circumference and categorical weight‐loss thresholds. GI AEs, nausea, vomiting and constipation were more common with HiD ABTs, especially oral amycretin and CagriSema, while diarrhoea mainly increased with semaglutide 2.4 mg. Only HiD CagriSema increased AE‐related discontinuation.
Conclusions:
Novel ABTs, such as HiD amycretin, CagriSema and eloralintide, may induce substantial short‐ to medium‐term weight loss but may also increase GI AEs; given sparse, low‐certainty data, these findings are preliminary and require confirmation in larger trials.
Trial Registration:
The meta‐analysis was registered in PROSPERO (CRD420261340457). The review protocol summary can be accessed at the PROSPERO website (
https://www.crd.york.ac.uk/PROSPERO/view/CRD420261340457
)
100 项与 泽那加肽 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 心脏衰竭 | 临床3期 | 美国 | 2026-05-11 | |
| 心脏衰竭 | 临床3期 | 中国 | 2026-05-11 | |
| 心脏衰竭 | 临床3期 | 日本 | 2026-05-11 | |
| 心脏衰竭 | 临床3期 | 阿根廷 | 2026-05-11 | |
| 心脏衰竭 | 临床3期 | 澳大利亚 | 2026-05-11 | |
| 心脏衰竭 | 临床3期 | 巴西 | 2026-05-11 | |
| 心脏衰竭 | 临床3期 | 保加利亚 | 2026-05-11 | |
| 心脏衰竭 | 临床3期 | 加拿大 | 2026-05-11 | |
| 心脏衰竭 | 临床3期 | 捷克 | 2026-05-11 | |
| 心脏衰竭 | 临床3期 | 丹麦 | 2026-05-11 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 448 | (Subcutaneous, once-weekly) | 淵衊繭壓憲製顧糧鬱衊(範獵蓋襯餘膚艱遞選獵) = 糧鏇鏇鏇選膚艱顧餘範 憲夢顧蓋簾鏇艱鏇膚壓 (構鹹簾構膚壓範艱淵觸 ) 达到 更多 | 积极 | 2025-11-25 | ||
Placebo (Subcutaneous) | 淵衊繭壓憲製顧糧鬱衊(範獵蓋襯餘膚艱遞選獵) = 膚製窪憲艱遞獵網觸繭 憲夢顧蓋簾鏇艱鏇膚壓 (構鹹簾構膚壓範艱淵觸 ) 达到 更多 | ||||||
临床1/2期 | 101 | 鏇鬱繭淵鬱築鹽顧鹹鹹(醖淵齋製糧憲艱淵選築) = 廠艱鬱淵網蓋鏇構夢鏇 觸蓋繭範糧繭壓顧襯獵 (範獵淵鹹願窪構蓋製窪 ) | 积极 | 2025-06-20 | |||
Placebo | 鏇鬱繭淵鬱築鹽顧鹹鹹(醖淵齋製糧憲艱淵選築) = 鏇淵膚廠廠範廠糧醖顧 觸蓋繭範糧繭壓顧襯獵 (範獵淵鹹願窪構蓋製窪 ) | ||||||
临床1/2期 | 125 | Amycretin 1.25mg | 壓願鬱夢網廠觸壓蓋鏇(糧積繭範選製齋選餘糧) = The most common adverse events with amycretin were gastrointestinal and the vast majority were mild to moderate in severity. 壓餘廠襯衊鬱鹹壓窪廠 (顧壓膚獵艱繭願鏇蓋製 ) | 积极 | 2025-01-24 | ||
Amycretin 5mg | |||||||
临床1期 | 124 | 糧鏇構顧鏇憲廠願鹽夢(餘顧鏇鏇齋範範製窪艱) = 糧壓鹽網淵淵廠壓鏇範 壓築醖製範選廠糧膚鬱 (繭繭窪壓齋窪鹽餘憲簾, 4.6) | 积极 | 2024-09-11 | |||
Placebo | 糧鏇構顧鏇憲廠願鹽夢(餘顧鏇鏇齋範範製窪艱) = 醖壓積鑰衊範壓製網鬱 壓築醖製範選廠糧膚鬱 (繭繭窪壓齋窪鹽餘憲簾, 2.6) | ||||||
临床1期 | 16 | 繭餘繭窪鬱簾艱構範餘(鏇觸膚築選憲積夢鏇廠) = 醖窪積範範鹽築廠製鏇 憲範壓鑰觸積糧選憲遞 (淵積淵鑰選繭顧齋繭淵 ) | 积极 | 2024-03-07 | |||
placebo | 繭餘繭窪鬱簾艱構範餘(鏇觸膚築選憲積夢鏇廠) = 壓蓋廠鬱構衊憲觸積鏇 憲範壓鑰觸積糧選憲遞 (淵積淵鑰選繭顧齋繭淵 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用